Tremfya Drug Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Tremfya (guselkumab) is a human monoclonal antibody that selectively binds to the p19 subunit of interleukin-23, inhibiting the IL-23/Th17 pathway that drives inflammatory immune responses. First approved by the U.S. FDA in 2017 for plaque psoriasis, it has since expanded to psoriatic arthritis, Crohn's disease, and most recently ulcerative colitis. Administered via subcutaneous injection at set intervals, Tremfya is marketed globally and has pediatric approval for patients as young as 6 years old weighing at least 40 kg, making it one of the more broadly indicated IL-23 inhibitors available.

• •Marketed by Janssen Pharmaceuticals (Johnson & Johnson), Tremfya competes in the IL-23 inhibitor class alongside products such as Skyrizi, Sotyktu, and others
• •The drug's label covers plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, spanning both dermatologic and gastrointestinal indications
• •Administered via subcutaneous injection, Tremfya offers dosing flexibility that supports patient adherence compared to more frequent regimens

The expanding global burden of autoimmune and inflammatory diseases is a primary driver of demand for targeted biologic therapies like Tremfya. Psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis collectively affect millions of people worldwide, with diagnosis rates increasing as awareness and access to specialty care improve. Advances in IL-23 targeted therapy have demonstrated superior efficacy and favorable safety profiles compared to older biologic classes, shifting treatment guidelines toward agents like Tremfya.

• •Rising global prevalence of psoriasis and inflammatory bowel diseases, coupled with improved diagnostic screening, is expanding the eligible patient population
• •Insurance coverage and reimbursement policies increasingly favor IL-23 inhibitors as preferred-line treatments for moderate to severe disease
• •Expansion into pediatric indications and additional disease areas broadens Tremfya's addressable market beyond its initial psoriasis approval

The IL-23 inhibitor and broader immune-mediated inflammatory disease market is segmented by therapeutic indication, with dermatology (psoriasis and psoriatic arthritis) representing the largest current segment and gastroenterology (Crohn's disease, ulcerative colitis) representing a fast-growing area. Regionally, North America leads in both market value and adoption of biologic therapies, supported by high healthcare spending, favorable reimbursement, and a large diagnosed patient population. Europe, Japan, and emerging markets across the Asia-Pacific and Latin American regions are also significant contributors, with growth rates varying based on regulatory approval timelines and healthcare access.

• •North America holds the largest share of the biologic market for inflammatory diseases, driven by early drug approvals, high treatment penetration, and strong payer coverage
• •Europe and Japan represent mature but growing markets with established regulatory pathways and high adoption of targeted immune therapies
• •Emerging markets in Asia-Pacific and Latin America are expanding access through regulatory approvals and healthcare infrastructure investment, though price sensitivity and reimbursement delays moderate growth

What are the recent trends and outlook?

The IL-23 inhibitor class is expected to remain a cornerstone of biologic treatment for inflammatory diseases, with continued innovation in formulation, dosing frequency, and route of administration. Biosimilar development for IL-23 targeting agents may eventually introduce price competition, though the complexity of biologic manufacturing and patent protections will likely delay this for several years. Expanding pediatric labeling, oral formulations under development across the class, and potential new indications in additional autoimmune conditions position the market for sustained long-term growth.

• •Emerging data on IL-23 inhibitors in additional autoimmune indications could further expand the addressable patient population beyond psoriasis and inflammatory bowel disease
• •Biosimilar entry for biologics in the IL-23 class is expected in the medium-to-long term, which may impact pricing dynamics but is tempered by the specialized manufacturing requirements of monoclonal antibodies
• •Healthcare systems are increasingly evaluating real-world outcomes and cost-effectiveness data, which will influence formulary decisions and market share among competing IL-23 and broader immune-targeting agents